Sant	82	REGIONAL ADULT PARENTERAL DRUG MONOGRAPH			
Southern Health		generic name cefuroxime			
Effective Date: May 201	An	SIFICATION tibiotic	OTHER NAM Zinace	f	
Revised Date: Jan 12 202 ADMINISTRATION				1 of 1	
IV Injection – May be administered by a nurse					
IV Infusion – May be administered by a nurse MINI-BAG PLUS COMPATIBLE					
IM Injection - May be administered by a nurse					
RECONSTITUTION/DILUTION/ADMINISTRATION:					
Available as:	θ				
		dd 8 mL sterile water for injection			
	Final Volume: 8	nal Volume: 8.3 mL <u>Final Concentration:</u> 90 mg/mL			
IV Bolus:	No further diluti	To further dilution required. Administer over 3 to 5 minutes			
IV Intermittent:	Dilute in 50 or 1	IINI-BAG PLUS COMPATIBLE Dilute in 50 or 100 mL normal saline. For fluid restricted patients dilute dose in 20 mL ormal saline. Administer over 20 to 60 minutes			
IM Injection:	-	50 mg vial dilute with 3 mL sterile injection inal Concentration: 225 mg/mL			
Maximum Rate:IV bolus:1500 mg over 3 minutesIV Intermittent:over 20 minutes					
Maximum Concentra		: IV: 100 mg/mL IM: 225 mg/mL			
DOSAGE:					
Usual:	750 to 1	500 mg IV eve	ry 8 hours		
Maximum single dose Maximum daily dose:					
STABILITY/COMPATIBILITY:					
Stability of Reconstituted Solution: 24 hours at room temperature					
Stability of Final Adm					
Compatibility (PARTIAL LISTING ONLY): Compatible with D5W, normal saline, dextrose-saline solutions and Ringer's Lactate					
PRECAUTIONS, POTENTIAL ADVERSE REACTIONS:					
Contraindicated in patients allergic to cephalosporins					
• Use cautiously in patients allergic to penicillin					
Hypersensitivity reactions including: rash, pruritus.					
Local reactions including phlebitis, pain.					
ADDITIONAL NOTES AND NURSING CONSIDERATIONS:					
 Dosage reduction is indicated in renal dysfunction. Beconstituted solution is light vallow to amber in color. 					
Reconstituted solution is light yellow to amber in color.IM injection may be painful.					
• IM injection may be painful.					

Approved by the Regional Pharmacy & Therapeutics Committee